Ping An Biomedical Plans to Buy Three Tumor-Related Patents for USD 2 Million–2.5 Million
Bitget2026/10/26 12:32- Ping An Biomedical signed a letter of intent to acquire three tumor-related medical technology patents from Future Biotechnology Group for USD 2 million–USD 2.5 million.
- The planned acquisition would establish a core oncology and biotechnology intellectual property portfolio to support longer-term healthcare development.
- No material near-term revenue is expected from the acquisition alone.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan Chief Global Strategist: Tech stock trading has entered a phase of volatility and uncertainty; investors should diversify their AI holdings
David Kelly, Chief Global Strategist at JPMorgan Asset Management, stated that as the artificial intelligence (AI) industry shows signs of entering a new phase characterized by increased volatility and rising technological uncertainty, investors should diversify their AI-related holdings.

New Zealand Dollar falls toward 18-month lows following RBNZ Q4 Inflation Expectations QoQ

Cramer Most Bearish on Stock Plummeting 61%: Intel (INTC.US) Lowers Guidance Amid Executive Stock Purchases
Jim Cramer called Intel his top stock pick, but its share price is down about 61% from its historical high. Intel lowered its Q4 revenue guidance to below $16.5 billion. CEO Pat Gelsinger recently bought 150,000 additional shares. Meanwhile, a shareholder lawsuit accuses the company of underestimating the weakness in the PC market.

Arthur Hayes Says 4 Crypto ‘Horsemen' Will Pump, Then Usher in AI Bubble's End
